Tisotumab vedotin extravasation injury in a patient with recurrent cervical cancer

被引：0
|
作者：
Son, Ji [1 ]
Cain, Katherine E. [2 ]
Marten, Claire A. [2 ]
Dwyer, Kaitlin W. [1 ]
Sims, Travis T. [1 ]
Taylor, Jolyn S. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Pharm Clin Programs, Houston, TX USA
来源：
GYNECOLOGIC ONCOLOGY REPORTS | 2024年 / 56卷
关键词：
SQUAMOUS-CELL-CARCINOMA; PREVIOUSLY TREATED RECURRENT; PHASE-II; TISSUE FACTOR; PERSISTENT; TRIAL;
D O I：
10.1016/j.gore.2024.101525
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Polatuzumab vedotin extravasation injury: a case report
    Toulmin, Sushila A.
    Nazir, Hana I.
    Abramson, Jeremy S.
    Soumerai, Jacob D.
    Freeman, Esther E.
    LEUKEMIA & LYMPHOMA, 2025,
  • [22] Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer
    Huo, Gengwei
    Liu, Wenjie
    Chen, Peng
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (05)
  • [23] Phase I/II trial of tisotumab vedotin plus bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8)
    Vergote, I. B.
    Concin, N.
    Mirza, M. R.
    Malmberg, A.
    Eaton, L.
    Nicacio, L.
    Lorusso, D.
    Soumaoro, I.
    Monk, B. J.
    O'Malley, D. M.
    ANNALS OF ONCOLOGY, 2019, 30 : 433 - 434
  • [24] A single arm, phase 2, multicenter, international trial of tisotumab vedotin (HuMax-TF-ADC) in previously treated, recurrent or metastatic cervical cancer.
    Coleman, Robert L.
    Concin, Nicole
    Herzog, Thomas J.
    Woelber, Linn Lena
    Mirza, Mansoor Raza
    Monk, Bradley J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] Safety and efficacy of tisotumab vedotin with cervical cancers: A systematic review and meta-analysis
    Mokresh, Muhammed Edib
    Alomari, Omar
    Varda, Abdullah
    Akdag, Goncagul
    Odabas, Hatice
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2024, 50 (12) : 2195 - 2210
  • [26] Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study
    Vergote, Ignace
    Van Nieuwenhuysen, Els
    O'Cearbhaill, Roisin E.
    Westermann, Anneke
    Lorusso, Domenica
    Ghamande, Sharad
    Collins, Dearbhaile C.
    Banerjee, Susana
    Mathews, Cara A.
    Gennigens, Christine
    Cibula, David
    Tewari, Krishnansu S.
    Madsen, Kristine
    Kose, Fatih
    Jackson, Amanda L.
    Boere, Ingrid A.
    Scambia, Giovanni
    Randall, Leslie M.
    Sadozye, Azmat
    Baurain, Jean-Francois
    Gort, Eelke
    Zikan, Michal
    Denys, Hannelore G.
    Ottevanger, Nelleke
    Forget, Frederic
    Andreassen, Camilla Mondrup
    Eaton, Lamar
    Chisamore, Michael J.
    Nicacio, Leonardo Viana
    Soumaoro, Ibrahima
    Monk, Bradley J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (36) : 5536 - +
  • [27] Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study
    Coleman, R. L.
    Lorusso, D.
    Gennigens, C.
    Gonzalez-Martin, A.
    Randall, L.
    Cibula, D.
    Lund, B.
    Woelber, L.
    Pignata, S.
    Forget, F.
    Redondo, A.
    Rangwala, R.
    Vindelov, S. D.
    Chen, M.
    Harris, J. R.
    Nicacio, L.
    Teng, M. S. L.
    Smith, M.
    Monk, B. J.
    Vergote, I. B.
    ANNALS OF ONCOLOGY, 2020, 31 : S1162 - S1163
  • [28] TISOTUMAB VEDOTIN COMBINATIONS WITH PEMBROLIZUMAB OR CARBOPLATIN IN PATIENTS WITH RECURRENT/METASTATIC CERVICAL CANCER: INTERIM RESULTS OF ENGOT CX8/GOG-3024 INNOVATV205
    Lorusso, Domenica
    Vergote, Ignace
    O'Cearbhaill, Rolsin E.
    Westermann, Anne M.
    Banerjee, Susana
    van Nieuwenhuysen, Els
    Iglesias, David A.
    Collins, Dearbhaile
    Cibula, David
    Madsen, Kristine
    Tewari, Krishnansu S.
    Pignata, Sandro
    Baurain, Jean-Francois
    Boere, Ingrid A.
    Denys, Hannelore
    Andreassen, Camilla Mondrup
    Soumaoro, Ibrahima
    Jain, Shweta
    Gennigens, Christine
    Monk, Bradley J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A57 - A58
  • [29] Tisotumab vedotin (TV) in patients with previously treated recurrent or metastatic cervical cancer: Updated safety and efficacy results from the full cervical cohort of the phase II innova TV 201 study (NCT02001623)
    Hong, D. S.
    Arkenau, H. T.
    de Bono, J.
    Lassen, U. N.
    Drew, Y.
    Slomovitz, B. M.
    Ghatta, S.
    Windfeld, K.
    Rangwala, R. A.
    Concin, N.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 11 - 12
  • [30] Phase 2 trial of tisotumab vedotin in platinum-resistant ovarian cancer (innovaTV 208).
    Mahdi, Haider
    Schuster, Steven Robert
    O'Malley, David M.
    McNamara, Donna M.
    Rangwala, Reshma A.
    Liang, Shang-Ying
    Jain, Shweta
    Nicacio, Leonardo
    Chon, Hye Sook
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345